Davis Polk advised the underwriters in the offering.Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq Global…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now